Hub genes and diagnostic model associated with mitochondrial function in Alzheimer's disease

Abstract

Background: Alzheimer's disease (AD) represents the most prevalent neurodegenerative disorder, with mitochondrial dysfunction being observed in both AD patients and mouse models. Nonetheless, further investigation is required to elucidate the pathogenic genes associated with AD and to develop early diagnostic methodologies centered on mitochondrial function.

Methods: In this study, the dataset GSE132903 was retrieved from the GEO database, encompassing both non-demented (ND) control and AD samples. Through the combination of differential expression gene analysis, weighted gene co-expression network analysis, and intersection with mitochondrial database gene sets, four hub genes associated with AD were identified. These four hub genes were subsequently validated in APP/PS1 and 5xFAD mouse models using molecular biology techniques.

Results: The hub genes identified through bioinformatics analysis include SYNJ2BP, VDAC1, NUBPL, and COX19. Within the GSE132903 dataset, the expression levels of SYNJ2BP, NUBPL, and COX19 were significantly elevated in the AD group compared to the non-demented (ND) group, whereas VDAC1 expression was reduced in the AD group relative to the ND group. Furthermore, in the hippocampus of APP/PS1 and 5xFAD mouse models, the expression patterns of SYNJ2BP and NUBPL were consistent with the bioinformatics analysis results.

Conclusion: Hub genes identified here through bioinformatics and molecular biology may help early diagnosis of AD patients and may also help build new AD models to explore its pathogenesis.

Keywords

Alzheimer's disease / diagnostic model / hub gene / mitochondria

References

[1] Gang W, Jinlei Q, Xinya L, et al. China Alzheimer Report 2024. Journal of Diagnostics Concepts & Practice. 2024; 23(3): 219-256.

[2] Krishnamurthy HK, Jayaraman V, Krishna K, et al. An overview of the genes and biomarkers in Alzheimer's disease. Ageing Res Rev. 2025; 104:102599.

[3] Zheng Q, Wang X. Alzheimer's disease: insights into pathology, molecular mechanisms, and therapy. Protein Cell. 2025; 16(2): 83-120.

[4] Calvin-Dunn KN, McNeela A, Leisgang Osse A, et al. Electrophysiological insights into Alzheimer's disease: a review of human and animal studies. Neurosci Biobehav Rev. 2025; 169:105987.

[5] Koskeridis F, Fancy N, Tan PF, et al. Multi-trait association analysis reveals shared genetic loci between Alzheimer's disease and cardiovascular traits. Nat Commun. 2024; 15(1): 9827.

[6] Gross EC, Lisicki M, Fischer D, Sándor PS, Schoenen J. The metabolic face of migraine - from pathophysiology to treatment. Nat Rev Neurol. 2019; 15(11): 627-643.

[7] Harris JJ, Jolivet R, Attwell D. Synaptic energy use and supply. Neuron. 2012; 75(5): 762-777.

[8] Tukacs V, Mittli D, Györffy BA, et al. Chronic stepwise cerebral hypoperfusion differentially induces synaptic proteome changes in the frontal cortex, occipital cortex, and hippocampus in rats. Sci Rep. 2020; 10(1): 15999.

[9] Chen B, de Launoit E, Meseguer D, et al. The interactions between energy homeostasis and neurovascular plasticity. Nat Rev Endocrinol. 2024; 20(12): 749-759.

[10] Wang W, Zhao F, Ma X, Perry G, Zhu X. Mitochondria dysfunction in the pathogenesis of Alzheimer's disease: recent advances. Mol Neurodegener. 2020; 15(1): 30.

[11] Xie W, Guo D, Li J, et al. CEND1 deficiency induces mitochondrial dysfunction and cognitive impairment in Alzheimer's disease. Cell Death Differ. 2022; 29(12): 2417-2428.

[12] D'Alessandro MCB, Kanaan S, Geller M, Praticò D, Daher JPL. Mitochondrial dysfunction in Alzheimer's disease. Ageing Res Rev. 2025; 107:102713.

[13] Pires M, Rego AC. Apoe4 and Alzheimer's disease pathogenesis-mitochondrial deregulation and targeted therapeutic strategies. Int J Mol Sci. 2023; 24(1):778.

[14] Xu M, Zhou H, Hu P, et al. Identification and validation of immune and oxidative stress-related diagnostic markers for diabetic nephropathy by WGCNA and machine learning. Front Immunol. 2023; 14:1084531.

[15] Chen G, Gou B, Du Y, et al. Predicting the molecular mechanism of ginger targeting PRMT1/BTG2 axis to inhibit gastric cancer based on WGCNA and machine algorithms. Phytomedicine. 2025; 143:156892.

[16] Gao CH, Chen C, Akyol T, et al. ggVennDiagram: intuitive Venn diagram software extended. iMeta. 2024; 3(1):e177.

[17] Gene Ontology Consortium: going forward. Nucleic Acids Res. 2015; 43(Database issue): D1049-D1056.

[18] Zhao X, Zhang L, Wang J, et al. Identification of key biomarkers and immune infiltration in systemic lupus erythematosus by integrated bioinformatics analysis. J Transl Med. 2021; 19(1): 35.

[19] de Jong A, Kuipers OP, Kok J. FUNAGE-pro: comprehensive web server for gene set enrichment analysis of prokaryotes. Nucleic Acids Res. 2022; 50(W1): W330-W336.

[20] Carlevaro-Fita J, Liu L, Zhou Y, et al. LnCompare: gene set feature analysis for human long non-coding RNAs. Nucleic Acids Res. 2019; 47(W1): W523-W529.

[21] Brusco MJ, Steinley D, Watts AL. A comparison of logistic regression methods for Ising model estimation. Behav Res Methods. 2023; 55(7): 3566-3584.

[22] Ye Z, Zhang H, Liang J, Yi S, Zhan X. Significance of logistic regression scoring model based on natural killer cell-mediated cytotoxic pathway in the diagnosis of colon cancer. Front Immunol. 2023; 14:1117908.

[23] Wang B, Zhou B, Chen J, et al. Type III interferon inhibits bladder cancer progression by reprogramming macrophage-mediated phagocytosis and orchestrating effective immune responses. J Immunother Cancer. 2024; 12(4): e007808.

[24] Zong Y, Li H, Liao P, et al. Mitochondrial dysfunction: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024; 9(1): 124.

[25] Zhang Y, Miao Y, Tan J, Chen F, Lei P, Zhang Q. Identification of mitochondrial related signature associated with immune microenvironment in Alzheimer's disease. J Transl Med. 2023; 21(1): 458.

[26] Um JH, Shin DJ, Choi SM, et al. Selective induction of Rab9-dependent alternative mitophagy using a synthetic derivative of isoquinoline alleviates mitochondrial dysfunction and cognitive deficits in Alzheimer's disease models. Theranostics. 2024; 14(1): 56-74.

[27] Cadonic C, Sabbir MG, Albensi BC. Mechanisms of mitochondrial dysfunction in Alzheimer's disease. Mol Neurobiol. 2016; 53(9): 6078-6090.

[28] Shen Y, Li HY, Yang QQ, et al. Unveiling Moxibustion's impact on AD mice learning and memory: role of mitochondrial respiratory chain complex I subunit in the hippocampus. Mol Neurobiol. 2025; 62: 13413-13429.

[29] Stojakovic A, Chang SY, Nesbitt J, et al. Partial inhibition of mitochondrial complex I reduces tau pathology and improves energy homeostasis and synaptic function in 3xTg-AD mice. J Alzheimer's Dis. 2021; 79(1): 335-353.

[30] Yi J, Wang HL, Lu G, et al. Spautin-1 promotes PINK1-PRKN-dependent mitophagy and improves associative learning capability in an alzheimer disease animal model. Autophagy. 2024; 20(12): 2655-2676.

[31] Mora-Romero B, Capelo-Carrasco N, Pérez-Moreno JJ, et al. Microglia mitochondrial complex I deficiency during development induces glial dysfunction and early lethality. Nat Metab. 2024; 6(8): 1479-1491.

[32] Trushina E, Trushin S, Hasan MF. Mitochondrial complex I as a therapeutic target for Alzheimer's disease. Acta Pharm Sin B. 2022; 12(2): 483-495.

[33] Chavda V, Lu B. Reverse electron transport at mitochondrial complex I in ischemic stroke, aging, and age-related diseases. Antioxidants (Basel). 2023; 12(4):895.

[34] Yao PJ, Eren E, Goetzl EJ, Kapogiannis D. Mitochondrial electron transport chain protein abnormalities detected in plasma extracellular vesicles in Alzheimer's disease. Biomedicine. 2021; 9(11):1587.

[35] Chen Z, Zhong C. Decoding Alzheimer's disease from perturbed cerebral glucose metabolism: implications for diagnostic and therapeutic strategies. Prog Neurobiol. 2013; 108: 21-43.

[36] Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metabolism. Nat Rev Cancer. 2011; 11(5): 325-337.

[37] Kumari S, Dhapola R, Reddy DH. Apoptosis in Alzheimer's disease: insight into the signaling pathways and therapeutic avenues. Apoptosis. 2023; 28(7–8): 943-957.

[38] Peng X, Guo H, Zhang X, et al. TREM2 inhibits tau hyperphosphorylation and neuronal apoptosis via the PI3K/Akt/GSK-3β signaling pathway in vivo and in vitro. Mol Neurobiol. 2023; 60(5): 2470-2485.

[39] Wang P, Shao Y, Al-Nusaif M, et al. Pathological characteristics of axons and alterations of proteomic and lipidomic profiles in midbrain dopaminergic neurodegeneration induced by WDR45-deficiency. Mol Neurodegener. 2024; 19(1): 62.

[40] Lai B, Wu D, Xiao Q, et al. Qiangji decoction mitigates neuronal damage, synaptic and mitochondrial dysfunction in SAMP8 mice through the regulation of ROCK2/Drp1-mediated mitochondrial dynamics. J Ethnopharmacol. 2025; 342:119424.

[41] Wang J, Liu J, Yang F, et al. GMRSP encoded by lncRNA H19 regulates metabolic reprogramming and alleviates aortic dissection. Nat Commun. 2025; 16(1): 1719.

[42] Hsu CG, Li W, Sowden M, Chávez CL, Berk BC. Pnpt1 mediates NLRP3 inflammasome activation by MAVS and metabolic reprogramming in macrophages. Cell Mol Immunol. 2023; 20(2): 131-142.

[43] Tian L, Long G, Zhu S, et al. Nanoimmunomodulation of the aβ-STING feedback machinery in microglia for Alzheimer's disease treatment. Proc Natl Acad Sci USA. 2025; 122(22):e2427257122.

RIGHTS & PERMISSIONS

2025 The Author(s). Animal Models and Experimental Medicine published by John Wiley & Sons Australia, Ltd on behalf of The Chinese Association for Laboratory Animal Sciences.